<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673439</url>
  </required_header>
  <id_info>
    <org_study_id>07.0100</org_study_id>
    <secondary_id>BCC-NON-07-001</secondary_id>
    <nct_id>NCT00673439</nct_id>
  </id_info>
  <brief_title>Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)</brief_title>
  <official_title>A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how safe and effective fondaparinux is in treating
      patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, standard treatment of HIT involves the transition from a direct thrombin inhibitor
      (a type of anticoagulant or &quot;blood thinner&quot;) to warfarin, a different type of anticoagulant.
      Direct thrombin inhibitors (DTIs) require IV administration and frequent blood draws for dose
      adjustments, which can lead to prolonged hospitalization. DTIs also affect blood test
      measurements, making it difficult to determine proper dosages of warfarin.

      Fondaparinux is a drug that is approved by the FDA for the treatment of blood clots in deep
      veins and in the lungs. Fondaparinux is not FDA approved for the treatment of HIT. However,
      an increasing number of doctors are using fondaparinux instead of DTIs to treat HIT. Although
      fondaparinux appears to be more convenient and predictable than DTI medications, more
      research is needed to support its use as a treatment for HIT.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study terminated due to low accrual
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Incidence of Clinically Significant Bleeding, Defined as Hemodynamically Significant Bleeding or Requiring Blood Transfusions While Being Treated With Fondaparinux</measure>
    <time_frame>at fondaparinux discontinuation</time_frame>
    <description>Study terminated, results data not available</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Incidence of Venous or Thrombotic Events After Starting Treatment With Fondaparinux</measure>
    <time_frame>4 weeks after INR reaches 2 or more</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Heparin-Induced Thrombocytopenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux</intervention_name>
    <description>Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2</description>
    <other_name>Arixtra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks</description>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  high risk for HIT based on &quot;Four Ts score&quot; of 6 or more

        Exclusion Criteria:

          -  pulmonary emboli at the time of enrollment

          -  arterial thrombosis at the time of enrollment

          -  limb threatening phlegmasia cerulea dolens at the time of enrollment

          -  Calculated Creatinin Clearance less than 50 ml/hr

          -  platelet count less than 50

          -  Weight less than 50 kg

          -  pregnancy

          -  allergy to fondaparinux

          -  bacterial endocarditis

          -  history of neuraxial anesthesia and post-operative indwelling epidural catheter

          -  active major bleeding (hemodynamically significant or requiring transfusions)

          -  inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goetz H Kloecker, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>May 3, 2013</results_first_submitted>
  <results_first_submitted_qc>May 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 24, 2013</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Goetz Kloecker</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>heparin-induced thrombocytopenia</keyword>
  <keyword>thrombocytopenia</keyword>
  <keyword>HIT</keyword>
  <keyword>thrombosis</keyword>
  <keyword>blood clot</keyword>
  <keyword>blood thinner</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>heparin</keyword>
  <keyword>warfarin</keyword>
  <keyword>fondaparinux</keyword>
  <keyword>Arixtra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daily Subcutaneous Injection of Fondaparinux (7.5-10 mg)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daily Subcutaneous Injection of Fondaparinux (7.5-10 mg)</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Over 18 years of age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Incidence of Clinically Significant Bleeding, Defined as Hemodynamically Significant Bleeding or Requiring Blood Transfusions While Being Treated With Fondaparinux</title>
        <description>Study terminated, results data not available</description>
        <time_frame>at fondaparinux discontinuation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daily Subcutaneous Injection of Fondaparinux (7.5-10 mg</title>
          </group>
        </group_list>
        <measure>
          <title>the Incidence of Clinically Significant Bleeding, Defined as Hemodynamically Significant Bleeding or Requiring Blood Transfusions While Being Treated With Fondaparinux</title>
          <description>Study terminated, results data not available</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incidence of Venous or Thrombotic Events After Starting Treatment With Fondaparinux</title>
        <time_frame>4 weeks after INR reaches 2 or more</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Daily Subcutaneous Injection of Fondaparinux (7.5-10 mg)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated, results data not available</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Goetz H Kloecker, MD, MSPH</name_or_title>
      <organization>James Graham Brown Cancer Center</organization>
      <phone>502/562-4358</phone>
      <email>ghkloe01@exchange.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

